Frontlight ResearchEarly access
CompletedNo phase
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
Key facts
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 400 people enrolled
- Started
- 31 Mar 2024
- Ended
- 10 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tegoprazan-amoxicillin dual therapy
- Record updated
- 5 March 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 18-65 years old
- Patients who have had a positive 13C or 14C breath test and have not received Helicobacter pylori eradication therapy before, or who have failed to eradicate in the early stage but have not received eradication therapy within half a year
- Voluntarily join this trial and sign the informed consent form
Who cannot take part
- Patients who have received Helicobacter pylori eradication therapy within half a year
- Use of antibiotics, bismuth, histamine H2 receptor antagonists or PPIs for 4 weeks before starting study treatment
- use of adrenocorticosteroids, non-steroidal anti-inflammatory drugs or anticoagulants
- Suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease
- Allergy to the study drug (penicillin, amoxicillin, furazolidone, Tegoprazan, etc.)
- Patients with active peptic ulcer disease
- History of esophageal or gastric surgery
- Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases
- Pregnant or lactating women
- Alcoholism
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and adverse drug reactions of H. pylori infection were compared in a multi-center clinical joint study in Jiangsu Province.
The 2 groups in the trial
- Group ATreatment being tested
oral Tegoprazan 50 mg, bid+amoxicillin 1000 mg, tid. The duration of treatment is 14 days.
Treatment: Tegoprazan-amoxicillin dual therapy
- Group BExisting treatment, for comparison
oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days.
Treatment: Tegoprazan-amoxicillin dual therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 5 March 2026